Do you want to read an article? Please log in or register.
Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent
Pulmonary Fibrosis
RECOMMENDED
Related content
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre
Swiss Med Wkly.
Guler S, Zumstein P, Berezowska S, Pöllinger A, Geiser T, Funke-Chambour M
doi: 10.4414/smw.2018.14577.
RECOMMENDED
Pulmonary Fibrosis
Risk factors for disease progression in idiopathic pulmonary fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Thorax.
Raghu G, Ley B, Brown KK, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Noble PW, Song JW, Wells AU, Whelan TP, Lynch DA, Humphries SM, Moreau E, Goodman K, Patterson SD, Smith V, Gong Q, Sundy JS, O'Riordan TG, Martinez FJ
doi: 10.1136/thoraxjnl-2019-213620.
RECOMMENDED
Pulmonary Fibrosis
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, Lunnon K, Lindsay MA, Wain LV, Tyrrell J, Scotton CJ
doi: 10.1016/S2213-2600(20)30364-7.Visit the original publication at ncbi.nlm.nih.gov
Pulmonary Fibrosis
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study
Eur Respir J.
Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C
doi: 10.1183/13993003.
RECOMMENDED
Interstitial Lung Disease
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A, RELIEF investigators.
doi: 10.1016/S2213-2600(20)30554-3
Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med.
Cottin V, Hansell DM, Sverzellati N, Weycker D, Antoniou KM, Atwood M, Oster G, Kirchgaessler KU, Collard HR, Wells AU
doi: 10.1164/
Interstitial Lung DiseaseBronchi
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease
BMC Pulm Med.
Sgalla G, Walsh SLF, Sverzellati N, Fletcher S, Cerri S, Dimitrov B, Nikolic D, Barney A, Pancaldi F, Larcher L, Luppi F, Jones MG, Davies D, Richeldi L
doi: 10.1186/s12890-018-0670-0.
RECOMMENDED
Pulmonary Fibrosis
Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters?
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Taha N, D'Amato D, Hosein K, Ranalli T, Sergiacomi G, Zompatori M, Mura M
doi: 10.1186/s12931-020-01371-7.